These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 31248681)

  • 1. Carbapenem use in extended-spectrum cephalosporin-resistant Enterobacterales infections in US hospitals and influence of IDSA guidance: a retrospective cohort study.
    Walker MK; Diao G; Warner S; Babiker A; Neupane M; Strich JR; Yek C; Kadri SS;
    Lancet Infect Dis; 2024 Aug; 24(8):856-867. PubMed ID: 38679036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreasing the time to achieve therapeutic vancomycin concentrations in critically ill patients: developing and testing of a dosing nomogram.
    Baptista JP; Roberts JA; Sousa E; Freitas R; Deveza N; Pimentel J
    Crit Care; 2014 Dec; 18(6):654. PubMed ID: 25475123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Making the case for precision dosing: visualizing the variability of cefepime exposures in critically ill adults.
    Chang J; Liu J; Alshaer MH; Venugopalan V; Maranchick N; Peloquin CA; Rhodes NJ; Scheetz MH
    J Antimicrob Chemother; 2023 Sep; 78(9):2170-2174. PubMed ID: 37449472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abbreviated Urine Collection Compared With 24-Hour Urine Collection for Measuring Creatinine Clearance in Adult Critically Ill Patients: A Systematic Review.
    Saad MO; Mohamed A; Mohamed Ibrahim MI
    Ann Pharmacother; 2024 Apr; ():10600280241241820. PubMed ID: 38619016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variation in Gentamicin Dosing and Monitoring in Pediatric Units across New South Wales.
    Saddi V; Preddy J; Dalton S; Connors J; Patterson S
    Pediatr Qual Saf; 2017; 2(2):e015. PubMed ID: 30229154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
    Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
    Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Plazomicin, Tigecycline, and Meropenem Pharmacodynamic Exposure against Carbapenem-Resistant Enterobacteriaceae in Patients with Bloodstream Infection or Hospital-Acquired/Ventilator-Associated Pneumonia from the CARE Study (ACHN-490-007).
    Kuti JL; Kim A; Cloutier DJ; Nicolau DP
    Infect Dis Ther; 2019 Sep; 8(3):383-396. PubMed ID: 31254273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children.
    Chiotos K; Hayes M; Gerber JS; Tamma PD
    J Pediatric Infect Dis Soc; 2020 Feb; 9(1):56-66. PubMed ID: 31872226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.
    Nicolau DP; Freeman CD; Belliveau PP; Nightingale CH; Ross JW; Quintiliani R
    Antimicrob Agents Chemother; 1995 Mar; 39(3):650-5. PubMed ID: 7793867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter Clinical Evaluation of ETEST Plazomicin (PLZ) for Susceptibility Testing of Enterobacterales.
    Blanchard LS; Van Belkum A; Dechaume D; Armstrong TP; Emery CL; Ying YX; Kresken M; Pompilio M; Halimi D; Zambardi G
    J Clin Microbiol; 2022 Jan; 60(1):e0183121. PubMed ID: 34757833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comprehensive Overview of Antibiotic Selection and the Factors Affecting It.
    Patel K; Bunachita S; Agarwal AA; Bhamidipati A; Patel UK
    Cureus; 2021 Mar; 13(3):e13925. PubMed ID: 33868859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plazomicin: a new aminoglycoside in the fight against antimicrobial resistance.
    Clark JA; Burgess DS
    Ther Adv Infect Dis; 2020; 7():2049936120952604. PubMed ID: 32953108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbapenem-Resistant Enterobacterales: Considerations for Treatment in the Era of New Antimicrobials and Evolving Enzymology.
    Lasko MJ; Nicolau DP
    Curr Infect Dis Rep; 2020 Feb; 22(3):6. PubMed ID: 32034524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Simulated Application of the Hartford Hospital Aminoglycoside Dosing Nomogram for Plazomicin Dosing Interval Selection in Patients With Serious Infections Caused by Carbapenem-Resistant Enterobacterales.
    Asempa TE; Kuti JL; Seroogy JD; Komirenko AS; Nicolau DP
    Clin Ther; 2019 Aug; 41(8):1453-1462. PubMed ID: 31248681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of the Hartford Hospital Nomogram for Plazomicin Dosing Interval Selection in Patients with Complicated Urinary Tract Infection.
    Asempa TE; Kuti JL; Seroogy JD; Komirenko AS; Nicolau DP
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-Daily Plazomicin for Complicated Urinary Tract Infections.
    Wagenlehner FME; Cloutier DJ; Komirenko AS; Cebrik DS; Krause KM; Keepers TR; Connolly LE; Miller LG; Friedland I; Dwyer JP;
    N Engl J Med; 2019 Feb; 380(8):729-740. PubMed ID: 30786187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plazomicin: an intravenous aminoglycoside antibacterial for the treatment of complicated urinary tract infections.
    Bilinskaya A; Linder KE; Kuti JL
    Expert Rev Anti Infect Ther; 2020 Aug; 18(8):705-720. PubMed ID: 32319833
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.